Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) today announced the initiation of PolarisDMD, the Company’s Phase 3 trial for edasalonexent in Duchenne ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE